記住我
Case Report
Dhakre V.W. · Galande S.T. · Patil V.G. · Shah N.C. · Rathod C. · Sethna K.S. · Amrapurkar A.D.
Pancreatic adeno- Mixed neuroendocrine non-endocrine (pMINEN) are extremely rare. [1] They are known to have distal metastasis at presentation and also have a comparatively lower survival rate as compared to similar staged neuroendocrine carcinoma, adenocarcinoma, and small cell lung tumor from which its treatment patterns are extrapolated. [2,3] Also, very less is known about its molecular structure and natural courses. There is a dearth of data about pMINEN in literature also there is a lack of large multicentral trials due to which the MINEN do not have a standard universal management protocol. We here discuss the clinical dilemmas that arise during diagnosis, reporting, and urge to formulate a multi-centric trial to formulate a focused protocolized approach. We here describe our encounter with a pancreatic head lesion which on immunohistochemically turned out to be a pMINEN with moderately differentiating ductal adenocarcinoma and low-grade neuroendocrine tumor. Radical R0 surgery with multimodal treatment (chemotherapy + radiotherapy) gains improved survival in long term.
The Author(s). Published by S. Karger AG, Basel
Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)